





Innovative Medizinische Forschung (IMF – MFM): “Diabetes and Angiogenesis: different responses to endothelin-1 (ET-1) and vascular endothelial growth factor (VEGF) and the role of hemeoxygenase-1 (HO-1)” (GS Di Marco, 2009)
Innovative Medizinische Forschung (IMF – MFM): “Anti-angiogenic effects of Angiotensinogen” (M Brand, 2007)